Correlation of Non-HLA Antibodies and Biopsy-Proven Antibody-Mediated Rejection
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
Meeting: 2022 American Transplant Congress
Abstract number: 239
Keywords: Antibodies, Rejection
Topic: Clinical Science » Heart » 63 - Heart and VADs: All Topics
Session Information
Session Name: Heart and VADs: All Topics II
Session Type: Rapid Fire Oral Abstract
Date: Monday, June 6, 2022
Session Time: 3:30pm-5:00pm
Presentation Time: 4:20pm-4:30pm
Location: Hynes Room 210
*Purpose: Non-HLA antibodies are seen in heart transplantation (HTx), but the clinical significance has not been established. In many cases, non-HLA antibodies are drawn, but it is not clear whether these antibodies are correlated to antibody mediated rejection (AMR) per endomyocardial biopsy (EMBx).
*Methods: Between 2015 and 2021, we identified 71 HTx patients who had non-HLA antibodies drawn within one week of the EMBx. Non-HLA antibodies were detected in 41 patients and included the following antibodies: AT1R (n=37), MICA (n=5), or positive HLA + non-HLA antibodies (n=15). These positive antibodies were compared to their negative counterparts and evaluated for correlation to the EMBx +/- 1 week. Echocardiographic findings at the time of EMBx were also assessed.
*Results: Positive non-HLA antibodies compared to negative non-HLA antibodies drawn at the time of EMBx had similar findings of AMR ≥1. Subgroup analysis of positive AT1R and positive MICA antibodies had similar findings as the whole group. Cardiac function was also found to be normal in most cases at the time of non-HLA antibodies detection. (See table.)
*Conclusions: Positive non-HLA antibodies do not appear to have a correlation with AMR findings. Furthermore, cardiac function remained normal in all cases.
| Positive non-HLA (n=41) | Negative non-HLA (n=30) | P-Value | |
| EF at time of EMBx | 55.6 ± 17.1 | 54.6 ± 13.6 | 0.798 |
| Incidence of AMR (%) | 22.0% | 13.3% | 0.354 |
| Positive MICA (n=5) | Negative MICA (n=41) | P-Value | |
| EF at time of EMBx | 53.0 ± 28.6 | 54.4 ± 16.3 | 0.863 |
| Incidence of AMR (%) | 0.0% | 14.6% | 0.359 |
| Positive AT1R (n=37) | Negative AT1R (n=30) | P-Value | |
| EF at time of EMBx | 57.0 ± 14.3 | 52.5 ± 16.4 | 0.235 |
| Incidence of AMR (%) | 24.3% | 13.3% | 0.258 |
| Positive HLA + non-HLA (n=15) | Positive non-HLA only (n=25) | P-Value | |
| EF at time of EMBx | 53.3 ± 16.8 | 56.6 ± 17.8 | 0.566 |
| Incidence of AMR (%) | 26.7% | 20.0% | 0.625 |
To cite this abstract in AMA style:
Patel N, Kittleson M, Patel J, Singer-Englar T, Kim S, Chang D, Kransdorf E, Megna D, Kobashigawa JA. Correlation of Non-HLA Antibodies and Biopsy-Proven Antibody-Mediated Rejection [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/correlation-of-non-hla-antibodies-and-biopsy-proven-antibody-mediated-rejection/. Accessed November 21, 2024.« Back to 2022 American Transplant Congress